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Editor of FEBS Letters since 2001Born in South Africa, Richard Marais moved to London, Eng-
land at the age of 13. He did his PhD at the Ludwig Institute
for Cancer Research with Peter Parker, and a post-doc fol-
lowed at the Imperial Cancer Research Fund with Richard
Treisman. Since 1992, Richard has been at the Institute for
Cancer Research, ﬁrst with Chris Marshall and now indepen-
dently with his own lab. Richard reviews papers for FEBS Let-
ters in the ﬁelds of cancer signalling, particularly with regard
to kinase cascades and also in cancer prodrug therapy.What does your lab do?
Our research focuses on BRAF, a protein that is mutated in 7%
of cancers, particularly in 70% of melanomas [1]. We use molec-
ular, cellular and structural biology to study the basic biology of
this protein. We worked with David Barford to solve the crystal
structure of the kinase domain of BRAF last year, and this gave
us a huge insight into its regulation and how mutations stimu-
late its activity [2]. The second part of our work involves trans-
lational research: we are developing novel drug inhibitors of
BRAF and a new form of gene-therapy called GDEPT [3]. This
research involves high-throughput screening, structure-based
drug design,medicinal chemistry and pharmacology.We do this
work in cooperation with Caroline Springer and her colleagues
and we have written our work up in a number of patents.How do mutations in BRAF cause cancer?
In cells, BRAF is normally trapped in an inactive conforma-
tion by an interaction between the glycine rich loop and the
activation segment in its kinase domain. When a threonine
in the activation segment is phosphorylated, this interaction
is disrupted and BRAF pops into an open, active conforma-
tion. The mutations found in cancer also disrupt this interac-
tion, allowing the active conformation to prevail.Valine 600 of BRAF is mutated to glutamic acid (V600E) in 90%
of melanomas, so how does sunlight mutate this residue so
selectively?
That is an incredibly important and unfathomable question-
why that one residue? Other mutations are as just as active
as V600E but are rarely found. It may not be due to sunlight
because V600E also occurs in 15% of colorectal cancers and
30% of thyroid cancers, where the sun clearly does not shine.
It is possible that the biology of the cells strongly select this
mutant because it happens to be eﬃcient at stimulating tumour
progression, or alternatively, this codon may simply be a frag-
ile hot-spot that is highly mutable.0014-5793/$32.00  2006 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2006.05.024How did you choose a career in science?
When I was in South Africa I was always interested in nature
but when I came to the UK, my interests switched more to
the biology behind things. My interest in genetics arose from
my chats a neighbour whose daughter had a genetic condi-
tion and had to go to Great Ormond Street Children’s Hos-
pital quite a lot, and although I never met her, those talks
resulted in my choosing to study genetics and microbiology
at university.What was the most pivotal moment in your career?
The last half year of my post-doc with Treisman, for sure. I did
one key experiment and knew I was onto something, but I only
had ﬁve months left on my contract. I worked 12–14 h a day,
six days a week, but slacked oﬀ to 10 h on Sundays (smiling). I
wanted a Cell paper and I got two [4,5]. It was an ideal time
because I knew things were going to work. I was completely
absorbed and I knew what I had to do.Did these cell papers aﬀect the way you thought about science?
Sure, I became a lot more interested in trying to dissect under-
lying biological mechanisms, ﬁnding a why behind what we
see. My research is still pretty molecular.How close are we to a cure for cancer?
Some cancers are already curable. Others may never be, and I
think we need to change our aims to managing those cancers
rather than curing them, much in the way that person with dia-
betes can manage their disease. The new, targeted drug thera-
pies are likely to only block the growth of tumours rather than
killing them. But if we can learn how these drugs work, we may
be able to develop strategies that provide even more eﬀective
therapies. For melanoma, the situation is urgent. Despite
extensive eﬀorts over the years, our success in curing mela-
noma has not improved since it was ﬁrst described by Samuel
Johnson in the early 19th century, Then, he stated ‘‘there is no
cure for the black cancer, and not even a hope remains’’.
Unfortunately this statement is more or less still true today.
But you know, I do have hope and I want to develop eﬀective
therapies for melanoma.Contact Information
The Institute of Cancer Research, 237 Fulham Road, London,
England, United Kingdom
E-mail address: richard.marais@icr.ac.ukReferences
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